NIH | Researchers at the National Institutes of Health have developed a new
and improved viral vector—a virus-based vehicle that delivers
therapeutic genes—for use in gene therapy for sickle cell disease. In
advanced lab tests using animal models, the new vector was up to 10
times more efficient at incorporating corrective genes into bone marrow
stem cells than the conventional vectors currently used, and it had a
carrying capacity of up to six times higher, the researchers report.
The development of the vector could make gene therapy for sickle cell
disease much more effective and pave the way for wider use of it as a
curative approach for the painful, life-threatening blood disorder.
Sickle cell disease affects about 100,000 people in the United States
and millions worldwide.
“Our new vector is an important breakthrough in the field of gene
therapy for sickle cell disease,” said study senior author John Tisdale,
M.D., chief of the Cellular and Molecular Therapeutic Branch at the
National Heart, Lung, and Blood Institute (NHLBI). “It’s the new kid on
the block and represents a substantial improvement in our ability to
produce high capacity, high efficiency vectors for treating this
devastating disorder.”
Researchers have used virus-based vehicles for years in gene therapy experiments, where they have been very effective at delivering therapeutic genes to bone marrow stem cells in the lab before returning them to the body. But there’s always room for improvement in their design in order to optimize effectiveness, Tisdale noted. He compared the new virus-based vehicle to a new and improved car that is also far easier and cheaper for the factory to produce.
The study was supported by the NHLBI and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), both part of the NIH. It was published online today in Nature Communications.
Researchers have used virus-based vehicles for years in gene therapy experiments, where they have been very effective at delivering therapeutic genes to bone marrow stem cells in the lab before returning them to the body. But there’s always room for improvement in their design in order to optimize effectiveness, Tisdale noted. He compared the new virus-based vehicle to a new and improved car that is also far easier and cheaper for the factory to produce.
The study was supported by the NHLBI and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), both part of the NIH. It was published online today in Nature Communications.
